Home Site map Contacts
 

Tacedinaline (CI-994)

CI-994

CI-994 (Acetyldinaline) is an anti-cancer drug which inhibits histone deacetylases. In vitro, CI-994 in combination with cytarabine (ara-C), daunorubicin and mitoxantrone, resulted in moderate synergism. In vivo, higher dosages of CI-994 induced complete remissions. CI-994/ara-C was very active against BNML (Brown Norway rat acute myelocytic leukemia). The combinations of CI-994/daunorubicin and CI-994/mitoxantrone were also active against BNML.

Synonyms: CI-994; PD-123654; GOE-5549; Acetyldinaline; 4-Acetamido-N-(2-aminophenyl)benzamide
Technical Data: Molecular Weight - 269.31; Molecular formula - C15H15N3O2; CAS No - 112522-64-2

Ordering Information: Product Number - EC-000.2116; Price and Availability: Inquire This product is also available to buy in bulk quantities.

Related Products: Suberoylanilide Hydroxamic Acid; MS-275 (Entinostat); BML-210; M344; MGCD0103 (Mocetinostat); PXD101 (Belinostat); LBH-589 (Panobinostat); Tubastatin A; Scriptaid; NSC 3852; NCH 51; HNHA; BML-281; CBHA; Salermide; Pimelic Diphenylamide; ITF2357 (Givinostat); PCI-24781; APHA Compound 8; Droxinostat; SB939.

References:
1. Hubeek I, et al. CI-994 (N-acetyl-dinaline) in combination with conventional anti-cancer agents is effective against acute myeloid leukemia in vitro and in vivo. Oncol Rep. 2008 Jun;19(6):1517-23.
2. Loprevite M, et al. In vitro study of CI-994, a histone deacetylase inhibitor, in non-small cell lung cancer cell lines. Oncol Res. 2005;15(1):39-48.
3. Kouraklis G, et al. Histone deacetylase inhibitors: a novel target of anticancer therapy (review). Oncol Rep. 2006 Feb;15(2):489-94.


Home  |  About Company  |  Contract Synthesis  |  Cheminformatics Services  |  Info for Chemists  |  Contacts  |  FAQ  |  Site Map

© 2004-2016 Exclusive Chemistry Ltd. All rights reserved.